Terns Pharmaceuticals said on Tuesday it will stop developing its experimental obesity drug after a mid-stage trial showed modest weight loss and raised safety concerns.

Celcuity expects to complete a rolling NDA submission for gedatolisib under the FDA RTOR program by Q4 2025. Click here to ...

According to new data, 73% of all participants in treatment courts did not commit another felony offense within five years of ...

Democratic-led states secured a legal victory to keep the personal data of food recipients out of the federal government's ...

The B.S. degree launched this fall as part of a long-term plan that began in 2017 with local industry approaching UNLV to ...

The partnership will enable NetApp and the 49ers Foundation to utilize the unique setting of Levi's® Stadium to provide ...

In President Donald Trump’s America, information that has been relied on for decades to make critical decisions has been ...

In a series of letters to administration officials, the Democrats, led by Sen. Patty Murray, D-Wash., the party’s top ...

From grounding orders to headline investigations, this aircraft's story is one of resilience and recovery. But is its future ...

The imbalance between energy supply and demand driven by data centers is the leading cause of your skyrocketing electricity ...

Appointed over the summer, Sudarshan Gopaladesikan has tasked himself with defining the DNA of the club's playing philosophy ...

Virginia’s statewide effort to curb gun violence is drawing national attention after new data shows a sharp drop in homicides ...